Common Side Effects of Tigecycline
Tigecycline, a glycylcycline antibiotic used for complicated skin infections, intra-abdominal infections, and community-acquired pneumonia, causes nausea (26%), vomiting (18%), and diarrhea (13%) more frequently than comparators in clinical trials.[1][2] Other frequent effects include headache (13%), abdominal pain (7%), and elevated liver enzymes (aspartate aminotransferase up 4%, alanine aminotransferase up 3%).[1]
Why Tigecycline Has Higher GI Issues
Its broad-spectrum activity disrupts gut flora more than beta-lactams or fluoroquinolones, leading to 2-3 times higher nausea/vomiting rates versus comparators like levofloxacin or piperacillin-tazobactam in phase 3 trials.[1][3] IV administration contributes, with symptoms often dose-related and peaking early in treatment.
Serious Risks Unique to Tigecycline
Increased mortality risk (4% vs 3% in comparators) prompted FDA warnings, linked to superinfections like ventilator-associated pneumonia.[1][4] Pancreatitis, hypersensitivity, and fetal toxicity (pregnancy category D) occur rarely but exceed rates in cephalosporins or carbapenems.[2] Avoid in children under 8 due to tooth discoloration.[1]
Tigecycline vs. Carbapenems (e.g., Imipenem)
Tigecycline shows higher GI intolerance (nausea 20-30% vs 5-10%) but lower C. difficile rates than carbapenems (1-2% vs 3-5%).[3][5] Carbapenems edge out on seizure risk (rare, <1%) while tigecycline raises pancreatitis odds.[2]
Tigecycline vs. Fluoroquinolones (e.g., Levofloxacin)
Fluoroquinolones have lower nausea (5-10% vs 25%) but higher tendon rupture (0.1-1%) and QT prolongation risks.[3][6] Tigecycline avoids these but increases hepatic issues (3% vs 1%).[1]
Tigecycline vs. Vancomycin for Skin Infections
Vancomycin causes more nephrotoxicity (5-15% vs <2% for tigecycline) and red man syndrome (5%).[5][7] Tigecycline leads in GI effects but matches on infusion reactions.
Patient Concerns and Management
Patients report tigecycline's nausea as more disruptive, often requiring antiemetics or slower infusions.[8] Monitor LFTs weekly; discontinue if transaminases exceed 5x ULN.[1] Not first-line due to mortality signal—reserve for multidrug-resistant cases.[4]
[1]: Tigecycline Prescribing Information (FDA)
[2]: Drugs.com - Tigecycline Side Effects
[3]: Taiwo et al., Clin Infect Dis (2008); doi:10.1086/529448
[4]: FDA Drug Safety Communication (2013)
[5]: Postma et al., J Antimicrob Chemother (2013); doi:10.1093/jac/dkt039
[6]: Levofloxacin Prescribing Information (FDA)
[7]: Vancomycin Prescribing Information (FDA)
[8]: RxList - Tygacil Patient Reviews